Decision Resources, a pharmaceutical and healthcare research and advisory firm, found therapies to treat chronic back pain and arthritis pain will continue to be the most profitable segments of the chronic pain drug market through 2020, according to a news release.
The overall market for chronic pain therapies is predicted to remain stable at approximately $20 billion. Chronic back pain and arthritis pain together account for nearly 57 percent of the overall chronic pain drug market in 2010. The report also found pain physicians are skeptical the government-mandated Risk Evaluation and Mitigation Strategy programs will change physician prescribing habits.
Related Articles on Pain Management:
Dr. Andrew C. Charles Named First Luskin Chair in Migraine and Headache Studies at UCLA
DSM Collaborates with AdeTherapeutics to Develop Pain Management and Scar
Reduction Product for Spine Surgeries
Neuros Medical Receives Approval for Pilot Study of Electrical Nerve Block Technology
The overall market for chronic pain therapies is predicted to remain stable at approximately $20 billion. Chronic back pain and arthritis pain together account for nearly 57 percent of the overall chronic pain drug market in 2010. The report also found pain physicians are skeptical the government-mandated Risk Evaluation and Mitigation Strategy programs will change physician prescribing habits.
Related Articles on Pain Management:
Dr. Andrew C. Charles Named First Luskin Chair in Migraine and Headache Studies at UCLA
DSM Collaborates with AdeTherapeutics to Develop Pain Management and Scar
Reduction Product for Spine Surgeries
Neuros Medical Receives Approval for Pilot Study of Electrical Nerve Block Technology